Mounjaro and Asthma: Can Tirzepatide Help?

Mounjaro and asthma may not seem like an obvious pairing. Yet a growing body of clinical evidence suggests that tirzepatide could improve respiratory outcomes for people living with both obesity and poorly controlled asthma. For many patients at CutKilo, breathing difficulties have accompanied excess weight for years. The connection between the two is more direct than most people realise.

In this article, Dr Emil Gadimali explains what the latest research tells us about GLP-1 receptor agonists and asthma. He covers why weight loss alone does not fully explain the benefit, and what this means for patients considering Mounjaro treatment.

Mounjaro is not licensed as an asthma treatment. No doctor would prescribe it solely for respiratory symptoms. However, research published in Advances in Therapy tells a compelling story. The study analysed over 60,000 primary care records and found that patients prescribed GLP-1 receptor agonists had fewer asthma exacerbations. They also required less rescue medication, even when weight loss was modest.

A separate study presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2026 conference confirmed these findings. GLP-1 agonists are associated with a reduced risk of asthma flare-ups in people with obesity who do not have diabetes.

The evidence points to a benefit that goes beyond weight loss. A direct anti-inflammatory effect on the airways likely plays a role. For CutKilo patients who also have asthma, this is a welcome secondary advantage of treatment.

Mechanical restriction

The relationship between excess weight and asthma is well established. NICE guidelines and the British Thoracic Society (BTS) both recognise obesity as a modifiable risk factor for poorly controlled asthma.

Excess abdominal fat physically restricts lung expansion. The diaphragm has less room to move when visceral fat accumulates around the abdomen. This reduces the amount of air left in the lungs after a normal breath and makes each inhalation feel more effortful.

Adipose-driven inflammation

Adipose tissue is metabolically active. It releases pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-alpha). These contribute to systemic inflammation. In the airways, this chronic low-grade inflammation amplifies the allergic response and increases bronchial hyperreactivity.

Reduced steroid effectiveness

People with obesity-related asthma often respond poorly to inhaled corticosteroids. A study in the Journal of Allergy and Clinical Immunology showed that standard steroid-based treatments are less effective in patients with higher BMI. This partly explains why this group experiences more frequent exacerbations and emergency visits.

The UK primary care study

The most compelling large-scale evidence comes from the University of Aberdeen, working with the Observational and Pragmatic Research Institute (OPRI). Their retrospective analysis appeared in Advances in Therapy. It examined data from the Optimum Patient Care Research Database (OPCRD), which holds records for over 28 million UK primary care patients.

The study compared asthma outcomes in more than 60,000 patients prescribed GLP-1 receptor agonists against matched controls over one year. The GLP-1 group showed lower rates of oral corticosteroid prescriptions, reduced need for rescue bronchodilator use, and fewer asthma-related healthcare contacts.

The average weight loss in the GLP-1 group was only 0.9 kg over the year. As Professor David Price noted: “We found compelling evidence that GLP-1s, as well as increasing weight loss, also improved asthma symptoms.” The modest weight change suggests that the respiratory benefit does not come from losing weight alone. Instead, GLP-1 agonists appear to reduce airway inflammation through a pathway distinct from corticosteroids.

Confirmation in non-diabetic patients

A study presented at the AAAAI 2026 conference confirmed these findings in a non-diabetic population. Patients with obesity and asthma who took GLP-1 medications had a significantly lower risk of asthma exacerbations than those who did not, after adjusting for weight change, age, sex, and comorbidities.

Vanderbilt University Medical Center is now conducting the first prospective clinical trial designed to test whether GLP-1 therapy improves asthma outcomes. This NIH-funded Phase 2 trial is enrolling up to 100 participants. It measures lung function, airway inflammation markers, and asthma symptom burden over 24 weeks of treatment. Results are expected by late 2026.

Tirzepatide, the active ingredient in Mounjaro, is a dual GIP/GLP-1 receptor agonist. Its primary action is on appetite regulation and glucose metabolism. However, GLP-1 receptors are found throughout the body, including in the lungs. Preclinical research is beginning to reveal how this might translate into respiratory benefits.

A laboratory study in Frontiers in Pharmacology showed that tirzepatide inhibited aeroallergen-induced allergic airway inflammation in a mouse model of obese asthma. The drug reduced eosinophilic infiltration, mucus production, and airway hyperresponsiveness. These are all hallmarks of allergic asthma. These effects occurred through mechanisms independent of weight change.

GLP-1 agonists also lower circulating levels of CRP (C-reactive protein) and other inflammatory markers. CutKilo patients routinely see CRP reductions during Mounjaro treatment. This systemic dampening of inflammation likely extends to the airways. For more detail on how tirzepatide affects inflammatory markers, see our article on Mounjaro and inflammation.

If you have asthma and are starting or already taking Mounjaro through CutKilo, keep these practical points in mind.

First, do not change your asthma medication without consulting the doctor who manages your respiratory care. The evidence on GLP-1 agonists and asthma is promising but preliminary. Mounjaro does not replace inhalers. Stopping or reducing your preventer inhaler without medical advice could trigger a dangerous exacerbation.

Second, monitor your symptoms. Many CutKilo patients report that their breathing improves within the first few months of treatment, sometimes before significant weight loss occurs. If you notice that you use your reliever inhaler less often, or that exercise feels easier, mention this at your next asthma review. Your GP or respiratory nurse may then consider stepping down your preventer therapy. This aligns with NICE guideline NG80 and BTS/SIGN recommendations, which advise regular reassessment of treatment intensity.

Third, know the difference between side effects and respiratory symptoms. Gastrointestinal side effects of Mounjaro, particularly nausea in the early weeks, can occasionally feel similar to chest tightness or breathlessness. If you experience new or worsening respiratory symptoms after starting Mounjaro, seek medical advice promptly.

The patients most likely to see respiratory improvements on Mounjaro have obesity-related asthma. This group tends to have a BMI above 30, adult-onset asthma, and a poor response to standard inhaler therapy. Their asthma is driven more by mechanical restriction and systemic inflammation than by classic allergic triggers.

Patients with coexisting obstructive sleep apnoea may also experience compounded benefits. Both conditions improve with weight loss and reduced airway inflammation. The SURMOUNT-OSA trial demonstrated that tirzepatide significantly reduced the severity of obstructive sleep apnoea. The respiratory improvements from that trial align with the asthma findings described here.

Conversely, patients with well-controlled, mild allergic asthma who are a healthy weight are less likely to notice a respiratory difference on Mounjaro. The drug appears most beneficial where obesity and inflammation are the primary drivers of poor asthma control.

Here is the single most important takeaway: if you have asthma and obesity, treating the obesity with Mounjaro may improve your asthma control in ways that go beyond what weight loss alone achieves. Evidence from over 60,000 UK patient records, combined with supporting laboratory data, suggests that tirzepatide has a direct anti-inflammatory effect on the airways.

Mounjaro is not prescribed for asthma. But CutKilo patients who also manage a respiratory condition should discuss these findings with both their weight-loss doctor and their asthma team. It may change how aggressively their asthma needs to be treated over time.

Can Mounjaro replace my asthma inhaler? No. Mounjaro is a weight-loss and diabetes medication, not a licensed asthma treatment. Continue using your preventer and reliever inhalers as prescribed. If your asthma improves during treatment, your GP or respiratory specialist can reassess your inhaler regimen at your next review.

How quickly might I notice breathing improvements on Mounjaro? Some patients report easier breathing within the first eight to twelve weeks. This is likely due to the anti-inflammatory effects of tirzepatide rather than mechanical relief from reduced body weight, which takes longer to become significant.

Does Mounjaro interact with any asthma medications? The MHRA Summary of Product Characteristics (SmPC) for tirzepatide does not list any direct interactions with inhaled corticosteroids, bronchodilators, or leukotriene receptor antagonists. However, Mounjaro slows gastric emptying. This can affect the absorption rate of some oral medications. If you take oral asthma medications such as montelukast, discuss timing with your prescriber.

Is the respiratory benefit specific to tirzepatide, or do all GLP-1 agonists help? The large UK study included patients on various GLP-1 receptor agonists, including semaglutide and liraglutide. Benefits appeared across the class. However, tirzepatide is a dual GIP/GLP-1 agonist. The preclinical data showing direct airway anti-inflammatory effects used tirzepatide specifically. Whether the dual mechanism provides additional respiratory benefit beyond single GLP-1 agonists is not yet clear.

Should I tell my asthma nurse that I am taking Mounjaro? Yes. Keeping your respiratory team informed about all medications ensures that any changes in your asthma control are interpreted correctly. It also means treatment adjustments can be made safely.